AmerisourceBergen expands biopharma services with US$1.29B PharmaLex acquisition

USA – US drug distributor AmerisourceBergen Corporation (ABC) has signed a definitive agreement to acquire PharmaLex Holding, for US$1.29 billion (€1.28 billion) in cash.

This deal, which is tipped to add US$0.15 to adjusted diluted earnings per share more than the final seven months of the subsequent year, furthers the biopharma service expansion agenda that AmerisourceBergen set out at its investor day earlier this year.

The transaction is expected to close by March 2023 and is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.

At the occasion, the organization identified biopharma solutions as a US$100 billion marketplace, with a compound annual development price of 5 to 10 percent that is properly positioned to target primarily based on its current hyperlinks to downstream clinical shoppers and upstream companies.

This would contribute to AmerisourceBergen’s previously disclosed fiscal year 2023 growth target from capital deployment.

ABC sees certain possibilities to add small businesses with the smaller and mid-sized biopharma businesses that are now essential to innovation.

On closing the deal, the results of PharmaLex will be included as a component within the International Healthcare Solutions sector of AmerisourceBergen.

This latest development will progress various AmerisourceBergen’s strategic imperatives and boost its position to gain substantial growth prospects in the biopharma market.

The deal will expand ABC’s global platform of biopharmaceutical services, and PharmaLex’s results will be reported as a component within ABC’s international healthcare solutions segment.

This approach will support its manufacturer partners throughout the pharmaceutical development and marketing processes.

An international team of scientific, regulatory, and safety and compliance (GxP) specialists, PharmaLex is based in Germany.

The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product.

Additionally, it aids clients in introducing products to international markets and varied patient populations by delivering tech-driven services spanning from clinical development consultation to marketing authorization.

The PharmaLex takeover will build upon the current European presence of AmerisourceBergen in pharmaceutical supply and biopharma manufacturer services expertise.

The company provides tech-enabled services ranging from clinical development consulting to marketing authorization, enabling clients to efficiently bring products to global markets and diverse patient populations.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.